Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center.

作者信息

Petrucci Maria Teresa, Martini Vincenza, Levi Anna, Gallucci Cristiano, Palumbo Giovanna, Del Bianco Patrizia, Torromeo Concetta, Foà Robin

出版信息

Leuk Lymphoma. 2007 Jan;48(1):180-2. doi: 10.1080/10428190601007570.

DOI:10.1080/10428190601007570

PMID:17325863

Abstract

摘要

相似文献

Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center.

Leuk Lymphoma. 2007 Jan;48(1):180-2. doi: 10.1080/10428190601007570.

Thalidomide administration for the treatment of resistant plasma cell leukemia.

Acta Haematol. 2003;109(3):153-5. doi: 10.1159/000069284.

Thalidomide gives food for thought in multiple myeloma.

Lancet Oncol. 2006 Apr;7(4):283-4. doi: 10.1016/s1470-2045(06)70631-3.

[Plasma cell leukaemia].

Ann Biol Clin (Paris). 2005 Sep-Oct;63(5):535-9.

Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.

Leuk Lymphoma. 2003 Jul;44(7):1147-9. doi: 10.1080/1042819031000067918.

The future role of thalidomide in multiple myeloma.

Acta Haematol. 2005;114 Suppl 1:18-22. doi: 10.1159/000087040.

Antitumor activity of thalidomide in refractory multiple myeloma.

N Engl J Med. 1999 Nov 18;341(21):1565-71. doi: 10.1056/NEJM199911183412102.

An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma.

Leuk Lymphoma. 2007 Jan;48(1):46-55. doi: 10.1080/10428190601001904.

Diabetic foot disease in a patient with multiple myeloma receiving thalidomide.

Haematologica. 2002 Feb;87(2):ELT07.

Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.

J Pharm Pharm Sci. 2011;14(1):78-89.

引用本文的文献

Current Status on Management of Primary Plasma Cell Leukemia.

Curr Oncol Rep. 2024 Sep;26(9):1104-1112. doi: 10.1007/s11912-024-01563-0. Epub 2024 Jul 2.

Plasma Cell Leukemia: A Review of 3 Cases Managed in Kenya.

Case Rep Hematol. 2021 Jul 27;2021:4843818. doi: 10.1155/2021/4843818. eCollection 2021.

Primary plasma cell leukemia: A case report and review of the literature.

Clin Case Rep. 2019 Jul 30;7(9):1702-1708. doi: 10.1002/ccr3.2339. eCollection 2019 Sep.

Primary Plasma Cell Leukemia: Identity Card 2016.

Curr Treat Options Oncol. 2016 Apr;17(4):19. doi: 10.1007/s11864-016-0392-6.

A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):6313-22. eCollection 2014.

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Leukemia. 2013 Apr;27(4):780-91. doi: 10.1038/leu.2012.336. Epub 2012 Nov 21.

Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents.

Rare Tumors. 2012 Jun 26;4(3):e39. doi: 10.4081/rt.2012.e39. Epub 2012 Aug 14.

How I treat plasma cell leukemia.

Blood. 2012 Sep 20;120(12):2376-89. doi: 10.1182/blood-2012-05-408682. Epub 2012 Jul 26.

Plasma cell leukaemia and other aggressive plasma cell malignancies.

Br J Haematol. 2010 Aug;150(4):418-27. doi: 10.1111/j.1365-2141.2010.08157.x.

Primary plasma cell leukemia and autologous stem cell transplantation.

Haematologica. 2010 May;95(5):804-9. doi: 10.3324/haematol.2009.013334.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验